Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-Ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.

Trial Profile

Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-Ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Sorafenib (Primary) ; Capecitabine
  • Indications Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
    • 08 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top